Clinical Trial

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 12 locations 2026-08-08
Trial Details
NCT Number NCT07235384
Lead Sponsor Zai Lab (Shanghai) Co., Ltd.
Conditions Atopic Dermatitis (AD)
Enrollment 84 participants
Start Date 2025-12-01
Primary Completion 2027-12-28 (estimated)
Study Completion 2027-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-07